Azelnidipine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Azelnidipine
Accession Number
DB09230
Type
Small Molecule
Groups
Approved, Investigational
Description

Azelnidipine is a dihydropyridine calcium channel blocker. It is sold in Japan by Daiichi-Sankyo pharmaceuticals, Inc. Unlike nicardipine, it has a gradual onset and has a long-lasting hypotensive effect, with little increase in heart rate.

Structure
Thumb
Synonyms
Not Available
External IDs
CS-905
International/Other Brands
Calblock
Categories
UNII
PV23P19YUG
CAS number
123524-52-7
Weight
Average: 582.657
Monoisotopic: 582.247834831
Chemical Formula
C33H34N4O6
InChI Key
ZKFQEACEUNWPMT-UHFFFAOYSA-N
InChI
InChI=1S/C33H34N4O6/c1-20(2)42-32(38)27-21(3)35-31(34)29(28(27)24-15-10-16-25(17-24)37(40)41)33(39)43-26-18-36(19-26)30(22-11-6-4-7-12-22)23-13-8-5-9-14-23/h4-17,20,26,28,30,35H,18-19,34H2,1-3H3
IUPAC Name
3-[1-(diphenylmethyl)azetidin-3-yl] 5-propan-2-yl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CC(C)OC(=O)C1=C(C)NC(N)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC1CN(C1)C(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of hypertension.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Azelnidipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Azelnidipine.Vet Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Azelnidipine.Approved, Investigational
AmobarbitalThe metabolism of Azelnidipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Azelnidipine.Approved, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Azelnidipine.Approved, Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Azelnidipine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Azelnidipine.Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Azelnidipine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Atosiban.Approved, Investigational
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Azelnidipine.Experimental
BarbexacloneThe metabolism of Azelnidipine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Azelnidipine can be increased when combined with Barbital.Illicit
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Azelnidipine.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Azelnidipine.Approved, Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Azelnidipine.Experimental
BucindololBucindolol may increase the hypotensive activities of Azelnidipine.Investigational
BunazosinBunazosin may increase the hypotensive activities of Azelnidipine.Investigational
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Azelnidipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Azelnidipine.Approved
Calcium AcetateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Azelnidipine.Withdrawn
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Azelnidipine.Experimental
CarbomycinThe metabolism of Azelnidipine can be decreased when combined with Carbomycin.Vet Approved
CarvedilolCarvedilol may increase the hypotensive activities of Azelnidipine.Approved, Investigational
CaseinThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Azelnidipine.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Azelnidipine.Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Azelnidipine.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Azelnidipine.Approved, Investigational
CimetidineThe serum concentration of Azelnidipine can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Azelnidipine can be decreased when combined with Clarithromycin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Azelnidipine.Approved
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Azelnidipine.Approved, Vet Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Azelnidipine.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Azelnidipine.Approved, Investigational, Vet Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Azelnidipine.Investigational
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Azelnidipine.Vet Approved
DoxazosinDoxazosin may increase the hypotensive activities of Azelnidipine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Azelnidipine.Approved
EfavirenzThe serum concentration of Azelnidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Azelnidipine.Approved
ErythromycinThe metabolism of Azelnidipine can be decreased when combined with Erythromycin.Approved, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Azelnidipine.Experimental
FluconazoleThe serum concentration of Azelnidipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Azelnidipine.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Azelnidipine.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Fluvastatin.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Azelnidipine.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Azelnidipine.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Azelnidipine.Approved, Vet Approved
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Azelnidipine.Experimental
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Azelnidipine.Approved, Withdrawn
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Azelnidipine.Approved, Investigational
HexobarbitalThe metabolism of Azelnidipine can be increased when combined with Hexobarbital.Approved
IndoraminIndoramin may increase the hypotensive activities of Azelnidipine.Withdrawn
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Azelnidipine.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Azelnidipine.Approved, Investigational
JosamycinThe metabolism of Azelnidipine can be decreased when combined with Josamycin.Approved, Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Azelnidipine.Approved, Investigational
KitasamycinThe metabolism of Azelnidipine can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Azelnidipine.Approved
LovastatinThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Lovastatin.Approved, Investigational
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Azelnidipine.Experimental
MethohexitalThe metabolism of Azelnidipine can be increased when combined with Methohexital.Approved
MethylphenobarbitalThe metabolism of Azelnidipine can be increased when combined with Methylphenobarbital.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Azelnidipine.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Azelnidipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Azelnidipine.Approved, Investigational, Vet Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Azelnidipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Azelnidipine.Vet Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Azelnidipine.Experimental
NafcillinThe metabolism of Azelnidipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Azelnidipine.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Azelnidipine.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Azelnidipine.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Azelnidipine.Investigational
NitroprussideAzelnidipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Azelnidipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Azelnidipine.Approved, Vet Approved
OleandomycinThe metabolism of Azelnidipine can be decreased when combined with Oleandomycin.Vet Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Azelnidipine.Experimental
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Azelnidipine.Approved
PafuramidineThe risk or severity of adverse effects can be increased when Pafuramidine is combined with Azelnidipine.Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Azelnidipine.Approved
PentobarbitalThe metabolism of Azelnidipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Azelnidipine can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Azelnidipine.Approved, Vet Approved
PitavastatinThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Pitavastatin.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Azelnidipine.Approved, Investigational, Vet Approved
PravastatinThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Pravastatin.Approved
PrazosinPrazosin may increase the hypotensive activities of Azelnidipine.Approved
PrimidoneThe metabolism of Azelnidipine can be increased when combined with Primidone.Approved, Vet Approved
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Azelnidipine.Experimental
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Azelnidipine.Experimental
RifabutinThe serum concentration of Azelnidipine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Azelnidipine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Azelnidipine can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Azelnidipine can be decreased when it is combined with Rifaximin.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Rosuvastatin.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Azelnidipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Azelnidipine.Approved, Vet Approved
SecobarbitalThe metabolism of Azelnidipine can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Azelnidipine.Approved
SilodosinSilodosin may increase the hypotensive activities of Azelnidipine.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Azelnidipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Azelnidipine.Approved, Investigational
SolithromycinThe metabolism of Azelnidipine can be decreased when combined with Solithromycin.Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Azelnidipine.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Azelnidipine.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Azelnidipine.Approved
TelithromycinThe metabolism of Azelnidipine can be decreased when combined with Telithromycin.Approved
TerazosinTerazosin may increase the hypotensive activities of Azelnidipine.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Azelnidipine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Azelnidipine.Approved
ThiamylalThe metabolism of Azelnidipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Azelnidipine can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Azelnidipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Azelnidipine.Approved
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Azelnidipine.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Azelnidipine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Azelnidipine.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Azelnidipine.Approved, Investigational
TylosinThe metabolism of Azelnidipine can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
UrapidilUrapidil may increase the hypotensive activities of Azelnidipine.Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Azelnidipine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura T: Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker. Jpn J Pharmacol. 1989 Sep;51(1):57-64. [PubMed:2810942]
External Links
KEGG Drug
D01145
PubChem Compound
65948
PubChem Substance
310265134
ChemSpider
59352
ChEBI
31247
ChEMBL
CHEMBL1275868
Wikipedia
Azelnidipine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionCardiovascular Disease (CVD) / High Blood Pressure (Hypertension)1
4CompletedPreventionCoronary Artery Atherosclerosis / High Blood Pressure (Hypertension)1
4RecruitingTreatmentCerebral Small Vessels Disease1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension) / Obstructive Sleep Apnea (OSA)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00082 mg/mLALOGPS
logP5.12ALOGPS
logP5.57ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)19.88ChemAxon
pKa (Strongest Basic)6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area137.03 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity172.06 m3·mol-1ChemAxon
Polarizability60.76 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0159-0900060000-c80c65ee0493cbc50569

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Dihydropyridinecarboxylic acids and derivatives / Nitrobenzenes / Nitroaromatic compounds / Aralkylamines / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Trialkylamines / Amino acids and derivatives / Azetidines
show 11 more
Substituents
Diphenylmethane / Nitrobenzene / Dihydropyridinecarboxylic acid derivative / Nitroaromatic compound / Dihydropyridine / Aralkylamine / Dicarboxylic acid or derivatives / Hydropyridine / Vinylogous amide / Alpha,beta-unsaturated carboxylic ester
show 30 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 10:13 / Updated on December 01, 2017 16:14